TY - JOUR
T1 - Brain tumors and circulating micrornas
T2 - a systematic review and diagnostic meta-analysis
AU - Aalami, Amir Hossein
AU - Abdeahad, Hossein
AU - Shoghi, Ali
AU - Mesgari, Mohammad
AU - Amirabadi, Amir
AU - Sahebkar, Amirhossein
N1 - Funding Information:
This paper was not funded. The authors sincerely appreciate Mr. Adel Minaie for his help with the design of the graphical abstract.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/1/11
Y1 - 2022/1/11
N2 - Purpose: Brain tumors (BT) are among the most prevalent cancers in recent years. Various studies have examined the diagnostic role of microRNAs in different diseases; however, their diagnostic role in BT has not been comprehensively investigated. This meta-analysis was performed to assess microRNAs in the blood of patients with BTs accurately. Methods: Twenty-six eligible studies were included for analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under curve (AUC), Q*index, summary receiver-operating characteristic (SROC) were assessed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. Results: The diagnostic accuracy of microRNA was high in identifying BT based on the pooled sensitivity 0.82 (95%CI: 0.816–0.84), specificity 0.82 (95%CI: 0.817–0.84), PLR 5.101 (95%CI: 3.99–6.51), NLR 0.187 (95%CI: 0.149–0.236), DOR 34.07 (95%CI: 22.56–51.43) as well as AUC (0.92), and Q*-index (0.86). Subgroup analyses were performed for sample types (serum/plasma), reference genes (RNU6, miR-39, and miR-24), and region to determine the diagnostic power of microRNAs in the diagnosis of BT using pooled sensitivity, specificity, PLR, NLR, AUC, and DOR. Conclusion: This meta-analysis suggested that circulating microRNAs might be potential markers for noninvasive early detection of BT.
AB - Purpose: Brain tumors (BT) are among the most prevalent cancers in recent years. Various studies have examined the diagnostic role of microRNAs in different diseases; however, their diagnostic role in BT has not been comprehensively investigated. This meta-analysis was performed to assess microRNAs in the blood of patients with BTs accurately. Methods: Twenty-six eligible studies were included for analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under curve (AUC), Q*index, summary receiver-operating characteristic (SROC) were assessed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. Results: The diagnostic accuracy of microRNA was high in identifying BT based on the pooled sensitivity 0.82 (95%CI: 0.816–0.84), specificity 0.82 (95%CI: 0.817–0.84), PLR 5.101 (95%CI: 3.99–6.51), NLR 0.187 (95%CI: 0.149–0.236), DOR 34.07 (95%CI: 22.56–51.43) as well as AUC (0.92), and Q*-index (0.86). Subgroup analyses were performed for sample types (serum/plasma), reference genes (RNU6, miR-39, and miR-24), and region to determine the diagnostic power of microRNAs in the diagnosis of BT using pooled sensitivity, specificity, PLR, NLR, AUC, and DOR. Conclusion: This meta-analysis suggested that circulating microRNAs might be potential markers for noninvasive early detection of BT.
KW - brain tumors
KW - Circulating microRNAs
KW - diagnostic biomarker
KW - glioblastoma
KW - glioma
UR - http://www.scopus.com/inward/record.url?scp=85122758608&partnerID=8YFLogxK
U2 - 10.1080/14737159.2022.2019016
DO - 10.1080/14737159.2022.2019016
M3 - Article
C2 - 34906021
AN - SCOPUS:85122758608
SN - 1473-7159
VL - 22
SP - 201
EP - 211
JO - EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
JF - EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
IS - 2
ER -
